-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by First Republic Investment Management Inc.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by First Republic Investment Management Inc.
First Republic Investment Management Inc. lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,408 shares of the medical research company's stock after buying an additional 188 shares during the period. First Republic Investment Management Inc.'s holdings in Bio-Rad Laboratories were worth $1,004,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. SeaCrest Wealth Management LLC acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth about $26,000. Private Trust Co. NA boosted its stake in shares of Bio-Rad Laboratories by 230.0% during the third quarter. Private Trust Co. NA now owns 66 shares of the medical research company's stock worth $28,000 after buying an additional 46 shares during the period. Atlas Capital Advisors LLC acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth about $50,000. Allworth Financial LP boosted its stake in shares of Bio-Rad Laboratories by 414.8% during the third quarter. Allworth Financial LP now owns 139 shares of the medical research company's stock worth $58,000 after buying an additional 112 shares during the period. Finally, Sentry Investment Management LLC boosted its stake in shares of Bio-Rad Laboratories by 16.5% during the second quarter. Sentry Investment Management LLC now owns 148 shares of the medical research company's stock worth $73,000 after buying an additional 21 shares during the period. Institutional investors and hedge funds own 64.35% of the company's stock.
Get Bio-Rad Laboratories alerts:Bio-Rad Laboratories Price Performance
BIO stock opened at $470.88 on Friday. The firm has a 50 day moving average of $432.84 and a 200-day moving average of $447.37. Bio-Rad Laboratories, Inc. has a 12-month low of $344.63 and a 12-month high of $670.61. The company has a current ratio of 5.50, a quick ratio of 4.30 and a debt-to-equity ratio of 0.14. The company has a market cap of $14.04 billion, a price-to-earnings ratio of -2.33 and a beta of 0.92.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. TheStreet downgraded shares of Bio-Rad Laboratories from a "c" rating to a "d+" rating in a research report on Thursday, October 27th. Credit Suisse Group reduced their price objective on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating for the company in a research report on Friday, October 28th. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, January 18th. Finally, Royal Bank of Canada assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, December 6th. They issued an "outperform" rating and a $565.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $651.25.Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Read More
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
第一共和投资管理公司(First Republic Investment Management Inc.)根据其最近提交给美国证券交易委员会的Form 13F文件，在第三季度增持了Bio-Rad实验室公司的股票8.5%。该公司持有这家医学研究公司2,408股股票，在此期间又购买了188股。截至最近一个季度末，First Republic Investment Management Inc.持有的Bio-Rad实验室股份价值1,004,000美元。
其他对冲基金也对他们在该公司的头寸进行了调整。Seacrest Wealth Management LLC在第二季度收购了Bio-Rad实验室价值约2.6万美元的新股。私人信托公司NA在第三季度将其在Bio-Rad实验室的持股增加了230.0%。私人信托公司NA现在拥有66股这家医疗研究公司的股票，价值28,000美元，在此期间又购买了46股。Atlas Capital Advisors LLC在第二季度收购了Bio-Rad实验室价值约5万美元的新股。Allworth Financial LP在第三季度将其在Bio-Rad实验室的股份增加了414.8%。Allworth Financial LP现在拥有139股这家医疗研究公司的股票，价值5.8万美元，在此期间又购买了112股。最后，Sentry Investment Management LLC在第二季度将其在Bio-Rad实验室的持股增加了16.5%。在此期间，哨兵投资管理公司又购买了21股，现在拥有148股这家医疗研究公司的股票，价值73,000美元。机构投资者和对冲基金持有该公司64.35%的股票。
到达Bio-Rad实验室警报：Bio-Rad实验室性价比
周五，Bio股价开盘报470.88美元。该公司的50日移动均线切入位在432.84美元，200日移动均线切入位在447.37美元。Bio-Rad实验室，Inc.的12个月低点为344.63美元，12个月高位为670.61美元。该公司的流动比率为5.50，速动比率为4.30，债务权益比率为0.14。该公司市值为140.4亿美元，市盈率为-2.33倍，贝塔系数为0.92。
华尔街分析师预测经济增长
一些股票研究分析师最近对该股发表了评论。华尔街在10月27日星期四的一份研究报告中将Bio-Rad实验室的股票评级从“c”下调至“d+”。瑞士信贷集团将Bio-Rad实验室股票的目标价从715.00美元下调至640.00美元，并在10月28日星期五的一份研究报告中为该公司设定了“跑赢大盘”的评级。在1月18日周三发布的一份研究报告中，StockNews.com将Bio-Rad实验室的股票评级从买入下调至持有。最后，加拿大皇家银行在12月6日(星期二)的一份研究报告中承担了对Bio-Rad实验室股票的报道。他们给出了“跑赢大盘”的评级，并为该公司设定了565.00美元的目标价。一名分析师对该股的评级为持有，四名分析师对该股的评级为买入。根据MarketBeat的数据，Bio-Rad实验室目前的共识评级为“中等买入”，共识目标价为651.25美元。Bio-Rad实验室公司简介
(获取评级)
Bio-Rad实验室公司致力于开发和生产用于生化、制药和其他生命科学研究应用的特殊化学品。它通过生命科学和临床诊断部门开展业务。生命科学部门开发、制造和销售试剂、仪器和实验室仪器。
阅读更多内容
- 免费获取StockNews.com关于Bio-Rad实验室的研究报告(BIO)
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
- 内部人士和机构收购金刚狼全球
每天收到Bio-Rad实验室的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bio-Rad实验室和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧